Chemoprevention in gastrointestinal adenocarcinoma: For few but not for all?

G. E. Bazuro, F. Torino, G. Gasparini, L. Capurso

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Despite the general progress of the last two decades in oncogenesis mechanism comprehension, in screening and surveillance programs, in technological support to diagnosis and in treatment protocols, the long-term survival of gastrointestinal (GI) cancer patients is not substantially changed. Therefore chemoprevention strategies still appear as a possible alternative to screening and surveillance programs in reducing the incidence and the mortality for GI cancer, at an acceptable cost/effectiveness ratio. The present review is focused on three GI cancers: esophageal adenocarcinoma, gastric cancer and colorectal cancer and their respective precarcinogenic lesions. The authors examine, for each neoplasia, the available chemopreventive agents, their mechanism of action in preventing cancer, the potential targets in the cell growth process, the cost/effectiveness ratio and, whenever present in literature, a comparison with other cancer prevention strategies. The authors conclude that, at present, with the available agents, chemoprevention is not indicated for all patients at low or moderate risk for GI cancer, and should not be considered as a substitute for endoscopic surveillance. In high-risk patients only, both chemoprevention and surveillance could be used. In future more specific agents and combined therapies should be tested in specific group of patients identified by their genomic susceptibility to develop cancer and responsiveness to therapy.

Original languageEnglish
Pages (from-to)429-444
Number of pages16
JournalMinerva Gastroenterologica e Dietologica
Volume54
Issue number4
Publication statusPublished - Dec 2008

Fingerprint

Gastrointestinal Neoplasms
Chemoprevention
Adenocarcinoma
Cost-Benefit Analysis
Neoplasms
Cell Growth Processes
Clinical Protocols
Stomach Neoplasms
Colorectal Neoplasms
Carcinogenesis
Survival
Mortality
Incidence
Therapeutics

Keywords

  • Chemoprevention
  • Gastrointestinal neoplasms
  • Outcome assessment (health care)

ASJC Scopus subject areas

  • Gastroenterology
  • Internal Medicine
  • Nutrition and Dietetics
  • Endocrinology, Diabetes and Metabolism

Cite this

Bazuro, G. E., Torino, F., Gasparini, G., & Capurso, L. (2008). Chemoprevention in gastrointestinal adenocarcinoma: For few but not for all? Minerva Gastroenterologica e Dietologica, 54(4), 429-444.

Chemoprevention in gastrointestinal adenocarcinoma : For few but not for all? / Bazuro, G. E.; Torino, F.; Gasparini, G.; Capurso, L.

In: Minerva Gastroenterologica e Dietologica, Vol. 54, No. 4, 12.2008, p. 429-444.

Research output: Contribution to journalArticle

Bazuro, GE, Torino, F, Gasparini, G & Capurso, L 2008, 'Chemoprevention in gastrointestinal adenocarcinoma: For few but not for all?', Minerva Gastroenterologica e Dietologica, vol. 54, no. 4, pp. 429-444.
Bazuro, G. E. ; Torino, F. ; Gasparini, G. ; Capurso, L. / Chemoprevention in gastrointestinal adenocarcinoma : For few but not for all?. In: Minerva Gastroenterologica e Dietologica. 2008 ; Vol. 54, No. 4. pp. 429-444.
@article{f423f7c47c6f4c0490c274b2b3eb8e24,
title = "Chemoprevention in gastrointestinal adenocarcinoma: For few but not for all?",
abstract = "Despite the general progress of the last two decades in oncogenesis mechanism comprehension, in screening and surveillance programs, in technological support to diagnosis and in treatment protocols, the long-term survival of gastrointestinal (GI) cancer patients is not substantially changed. Therefore chemoprevention strategies still appear as a possible alternative to screening and surveillance programs in reducing the incidence and the mortality for GI cancer, at an acceptable cost/effectiveness ratio. The present review is focused on three GI cancers: esophageal adenocarcinoma, gastric cancer and colorectal cancer and their respective precarcinogenic lesions. The authors examine, for each neoplasia, the available chemopreventive agents, their mechanism of action in preventing cancer, the potential targets in the cell growth process, the cost/effectiveness ratio and, whenever present in literature, a comparison with other cancer prevention strategies. The authors conclude that, at present, with the available agents, chemoprevention is not indicated for all patients at low or moderate risk for GI cancer, and should not be considered as a substitute for endoscopic surveillance. In high-risk patients only, both chemoprevention and surveillance could be used. In future more specific agents and combined therapies should be tested in specific group of patients identified by their genomic susceptibility to develop cancer and responsiveness to therapy.",
keywords = "Chemoprevention, Gastrointestinal neoplasms, Outcome assessment (health care)",
author = "Bazuro, {G. E.} and F. Torino and G. Gasparini and L. Capurso",
year = "2008",
month = "12",
language = "English",
volume = "54",
pages = "429--444",
journal = "Minerva Gastroenterologica",
issn = "0026-4776",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "4",

}

TY - JOUR

T1 - Chemoprevention in gastrointestinal adenocarcinoma

T2 - For few but not for all?

AU - Bazuro, G. E.

AU - Torino, F.

AU - Gasparini, G.

AU - Capurso, L.

PY - 2008/12

Y1 - 2008/12

N2 - Despite the general progress of the last two decades in oncogenesis mechanism comprehension, in screening and surveillance programs, in technological support to diagnosis and in treatment protocols, the long-term survival of gastrointestinal (GI) cancer patients is not substantially changed. Therefore chemoprevention strategies still appear as a possible alternative to screening and surveillance programs in reducing the incidence and the mortality for GI cancer, at an acceptable cost/effectiveness ratio. The present review is focused on three GI cancers: esophageal adenocarcinoma, gastric cancer and colorectal cancer and their respective precarcinogenic lesions. The authors examine, for each neoplasia, the available chemopreventive agents, their mechanism of action in preventing cancer, the potential targets in the cell growth process, the cost/effectiveness ratio and, whenever present in literature, a comparison with other cancer prevention strategies. The authors conclude that, at present, with the available agents, chemoprevention is not indicated for all patients at low or moderate risk for GI cancer, and should not be considered as a substitute for endoscopic surveillance. In high-risk patients only, both chemoprevention and surveillance could be used. In future more specific agents and combined therapies should be tested in specific group of patients identified by their genomic susceptibility to develop cancer and responsiveness to therapy.

AB - Despite the general progress of the last two decades in oncogenesis mechanism comprehension, in screening and surveillance programs, in technological support to diagnosis and in treatment protocols, the long-term survival of gastrointestinal (GI) cancer patients is not substantially changed. Therefore chemoprevention strategies still appear as a possible alternative to screening and surveillance programs in reducing the incidence and the mortality for GI cancer, at an acceptable cost/effectiveness ratio. The present review is focused on three GI cancers: esophageal adenocarcinoma, gastric cancer and colorectal cancer and their respective precarcinogenic lesions. The authors examine, for each neoplasia, the available chemopreventive agents, their mechanism of action in preventing cancer, the potential targets in the cell growth process, the cost/effectiveness ratio and, whenever present in literature, a comparison with other cancer prevention strategies. The authors conclude that, at present, with the available agents, chemoprevention is not indicated for all patients at low or moderate risk for GI cancer, and should not be considered as a substitute for endoscopic surveillance. In high-risk patients only, both chemoprevention and surveillance could be used. In future more specific agents and combined therapies should be tested in specific group of patients identified by their genomic susceptibility to develop cancer and responsiveness to therapy.

KW - Chemoprevention

KW - Gastrointestinal neoplasms

KW - Outcome assessment (health care)

UR - http://www.scopus.com/inward/record.url?scp=59749094777&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59749094777&partnerID=8YFLogxK

M3 - Article

C2 - 19047983

AN - SCOPUS:59749094777

VL - 54

SP - 429

EP - 444

JO - Minerva Gastroenterologica

JF - Minerva Gastroenterologica

SN - 0026-4776

IS - 4

ER -